Ben Johnson Cites Caleb Williams

Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.
Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...
The 47-year-old millionaire tech mogul posted screenshots showing data from an overnight erection-tracking machine for both himself and his 19-year-old son, Talmage.
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
Raymond James lowered the firm’s price target on Johnson & Johnson to $165 from $170 and keeps an Outperform rating on the shares.
Johnson & Johnson unveiled financial results that beat Wall Street expectations as the company braces for one of its ...
Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.
Good morning and welcome to Johnson & Johnson's fourth quarter 2024 earnings conference call. All participants will be in a ...